MD20160014A2 - Virus ARN oncolitic stabil genetic, metodă de producere şi de utilizare a acestuia - Google Patents

Virus ARN oncolitic stabil genetic, metodă de producere şi de utilizare a acestuia

Info

Publication number
MD20160014A2
MD20160014A2 MDA20160014A MD20160014A MD20160014A2 MD 20160014 A2 MD20160014 A2 MD 20160014A2 MD A20160014 A MDA20160014 A MD A20160014A MD 20160014 A MD20160014 A MD 20160014A MD 20160014 A2 MD20160014 A2 MD 20160014A2
Authority
MD
Moldova
Prior art keywords
virus
manufacturing
human
rna virus
modified
Prior art date
Application number
MDA20160014A
Other languages
English (en)
Russian (ru)
Other versions
MD4480C1 (ro
MD4480B1 (ro
Inventor
Дите Венскус
Иварс Калвинс
Дасе ПЯНОВА
Рамона Петровска
Юргис АУЗИНС
Original Assignee
Ditesan Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ditesan Ltd. filed Critical Ditesan Ltd.
Publication of MD20160014A2 publication Critical patent/MD20160014A2/ro
Publication of MD4480B1 publication Critical patent/MD4480B1/ro
Publication of MD4480C1 publication Critical patent/MD4480C1/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se revendică o metodă de producere a enterovirusului modificat ECHO tip 7 prin modificarea virusului nativ ECHO 7 izolat printr-o metodă cunoscută din fecale umane şi identificat în baza secvenţei genomului, unde modificarea se realizează iniţial prin adaptarea virusului în celulele canceroase atenuate cu preparatul antitumoral dacarbazină, apoi virusul modificat este trecut în cultură de fibroblaşti embrionari umani cu reproducerea ulterioară în celule de melanom uman şi pasajul ulterior în cultură de fibroblaşti embrionari umani tratată cu ribavirină, izolarea şi purificarea printr-o metodă cunoscută. Virusul modificat este util în tratamentul unui şir de tumori.
MDA20160014A 2013-07-16 2014-07-16 Virus ARN oncolitic stabil genetic, metodă de producere şi de utilizare a acestuia MD4480C1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13176757.6A EP2826856B9 (en) 2013-07-16 2013-07-16 Genetically stable oncolytic RNA virus, method of manufacturing and use thereof
PCT/EP2014/065277 WO2015007788A1 (en) 2013-07-16 2014-07-16 Genetically stable oncolytic rna virus, method of manufacturing and use thereof

Publications (3)

Publication Number Publication Date
MD20160014A2 true MD20160014A2 (ro) 2016-07-31
MD4480B1 MD4480B1 (ro) 2017-05-31
MD4480C1 MD4480C1 (ro) 2017-12-31

Family

ID=48790285

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20160014A MD4480C1 (ro) 2013-07-16 2014-07-16 Virus ARN oncolitic stabil genetic, metodă de producere şi de utilizare a acestuia

Country Status (16)

Country Link
US (2) US10174291B2 (ro)
EP (2) EP2826856B9 (ro)
JP (1) JP6293882B2 (ro)
CN (2) CN110129284A (ro)
AU (1) AU2014292114B2 (ro)
BR (1) BR112016000874B1 (ro)
CA (1) CA2917584C (ro)
EA (1) EA032977B1 (ro)
ES (1) ES2566146T3 (ro)
GE (1) GEP201706763B (ro)
HK (1) HK1219500A1 (ro)
MD (1) MD4480C1 (ro)
MX (1) MX365075B (ro)
PL (2) PL2826856T3 (ro)
UA (1) UA116387C2 (ro)
WO (1) WO2015007788A1 (ro)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109276580B (zh) * 2017-07-21 2021-08-24 厦门大学 一种用于治疗肿瘤的病毒
CN109419818B (zh) * 2017-08-24 2021-08-10 厦门大学 一种用于治疗肿瘤的埃可病毒
CN107669707A (zh) * 2017-11-16 2018-02-09 邹罡 埃可病毒作为溶瘤病毒在抗肿瘤中的应用
CN110064044B (zh) * 2018-01-20 2022-09-09 中国科学院武汉病毒研究所 一种肠道病毒71型的抑制剂及应用
GB201808500D0 (en) 2018-05-23 2018-07-11 Ditesan Ltd Virus and virus use
WO2020035423A1 (en) 2018-08-13 2020-02-20 Ditesan Ltd. Combination therapy of cancer by administrating echo-7 virus and a pharmaceutically effective anti-cancer drug

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987101A (en) 1988-12-16 1991-01-22 International Business Machines Corporation Method for providing improved insulation in VLSI and ULSI circuits
CN1244583A (zh) * 1998-08-12 2000-02-16 财团法人生物技术开发中心 本土性猪水泡病病毒与其变异株的制备方法及用途
MXPA02002772A (es) * 1999-09-17 2004-04-02 Pro Virus Inc Virus oncolitico.
AUPQ425699A0 (en) * 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US6602862B1 (en) * 2000-09-19 2003-08-05 Merz Pharma Gmbh & Co., Kgaa 1-Amino-alkylcyclohexanes as trypanocidal agents
AU2002306709A1 (en) * 2001-03-14 2002-09-24 Replicon Technologies, Inc. Oncolytic rna replicons
LV12861B (lv) * 2002-06-14 2002-10-20 Aina Muceniece Imūnstimulators ar pretaudzēja aktivitāti un tā iegūšanas paņēmiens
AU2002953436A0 (en) * 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
PT1620456E (pt) * 2003-04-18 2014-04-15 Biotech Synergy Inc Péptidos antigénicos hla-a2 associados a tumor e suas composições
CN101132798B (zh) * 2005-01-17 2011-04-27 溶瘤病毒有限公司 核酸分子在制备用于治疗黑色素瘤的药物中的应用及其组合物
WO2008080003A2 (en) * 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Generation of oncolytic adenoviruses and uses thereof
US10722562B2 (en) * 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
CA2689707A1 (en) * 2009-11-16 2011-05-16 Jean-Simon Diallo Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening

Also Published As

Publication number Publication date
MX2016000462A (es) 2016-07-26
US20160376562A1 (en) 2016-12-29
EP3022297C0 (en) 2023-07-05
CN105518128A (zh) 2016-04-20
PL3022297T3 (pl) 2023-12-18
HK1219500A1 (zh) 2017-04-07
CN105518128B (zh) 2019-07-09
MD4480C1 (ro) 2017-12-31
EP3022297A1 (en) 2016-05-25
AU2014292114A1 (en) 2016-02-18
JP2016529886A (ja) 2016-09-29
EP2826856B9 (en) 2016-05-04
BR112016000874A2 (pt) 2017-03-21
JP6293882B2 (ja) 2018-03-14
UA116387C2 (uk) 2018-03-12
AU2014292114B2 (en) 2018-12-20
EP2826856B1 (en) 2015-12-23
US10435672B2 (en) 2019-10-08
MD4480B1 (ro) 2017-05-31
EP3022297B1 (en) 2023-07-05
ES2566146T3 (es) 2016-04-11
BR112016000874B1 (pt) 2019-07-16
CA2917584A1 (en) 2015-01-22
EP2826856A1 (en) 2015-01-21
CA2917584C (en) 2018-02-27
EA032977B1 (ru) 2019-08-30
US10174291B2 (en) 2019-01-08
MX365075B (es) 2019-05-22
PL2826856T3 (pl) 2016-06-30
EA201690232A1 (ru) 2016-05-31
US20190144833A1 (en) 2019-05-16
WO2015007788A1 (en) 2015-01-22
GEP201706763B (en) 2017-10-25
CN110129284A (zh) 2019-08-16

Similar Documents

Publication Publication Date Title
MD20160014A2 (ro) Virus ARN oncolitic stabil genetic, metodă de producere şi de utilizare a acestuia
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
PH12015502087A1 (en) Newcastle disease viruses and uses thereof
MX2020006117A (es) Integracion dirigida de acidos nucleicos.
MX2018004600A (es) Celulas aniquiladoras naturales y células ilc3 y usos de las mismas.
EA201791443A1 (ru) Естественные киллерные клетки и их применения
MX2018012880A (es) Metodos para proporcionar arn de hebra sencilla.
PH12015501953A1 (en) Substituted nucleotide analogs
MX2015001871A (es) Celulas asesinas naturales y usos de las mismas.
WO2014123967A3 (en) Cell lines for virus production and methods of use
MX2011010908A (es) Anticuerpos anti-tnf-alfa y sus usos.
IN2012DN01920A (ro)
MX354267B (es) Nucléosidos, nucleótidos, y ácidos nucleicos modificados, y usos de los mismos.
AR082340A1 (es) Metodos y composiciones para la terapia del cancer de higado
MX353476B (es) Anticuerpos anti-cxcl13 y metodos para usarlos.
EA201590747A1 (ru) Способы лечения с использованием аденовируса
MX342131B (es) Eliminacion selectiva de celulas erosivas.
EA201001266A1 (ru) Эффективные противоопухолевые парамиксовирусы
EA201891335A1 (ru) Добавление аргинина с целью повышения эффективности ацетогенов, ферментирующих газ
MX2013004906A (es) Nuevos inhibidores especificos de la proteasa ns3 de hcv.
MX359337B (es) Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer.
MX2023012266A (es) Un fab anti-tslp con estabilidad mejorada.
GR1008177B (el) Μεθοδος επεξεργασιας φυτικων προϊοντων με βαση την ελατη για παραγωγη εκχυλισματος με βιολογικες δρασεις και χρηση του για τη θεραπεια νοσων στον ανθρωπο και στα ζωα.
MY185444A (en) Enterovirus 71 antiviral peptides
NZ622284A (en) Novel plant defensins and use in the treatment of proliferative diseases

Legal Events

Date Code Title Description
FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees